AU2012206945B2 - Combination therapy - Google Patents

Combination therapy Download PDF

Info

Publication number
AU2012206945B2
AU2012206945B2 AU2012206945A AU2012206945A AU2012206945B2 AU 2012206945 B2 AU2012206945 B2 AU 2012206945B2 AU 2012206945 A AU2012206945 A AU 2012206945A AU 2012206945 A AU2012206945 A AU 2012206945A AU 2012206945 B2 AU2012206945 B2 AU 2012206945B2
Authority
AU
Australia
Prior art keywords
ccr2
pharmaceutical composition
angiotensin receptor
pathway inhibitor
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012206945A
Other languages
English (en)
Other versions
AU2012206945A1 (en
Inventor
Elizabeth Mccall
Kevin Donald George Pfleger
James Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dimerix Bioscience Pty Ltd
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46506697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2012206945(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2011900060A external-priority patent/AU2011900060A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Priority to AU2012206945A priority Critical patent/AU2012206945B2/en
Publication of AU2012206945A1 publication Critical patent/AU2012206945A1/en
Application granted granted Critical
Publication of AU2012206945B2 publication Critical patent/AU2012206945B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/80—Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012206945A 2011-01-11 2012-01-11 Combination therapy Active AU2012206945B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2012206945A AU2012206945B2 (en) 2011-01-11 2012-01-11 Combination therapy

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
AU2011900060 2011-01-11
AU2011900060A AU2011900060A0 (en) 2011-01-11 Combination Therapy
US201161432896P 2011-01-14 2011-01-14
US61/432,896 2011-01-14
US201161547951P 2011-10-17 2011-10-17
AU2011904279 2011-10-17
AU2011904279A AU2011904279A0 (en) 2011-10-17 Combination Therapy
US61/547,951 2011-10-17
PCT/AU2012/000014 WO2012094703A1 (en) 2011-01-11 2012-01-11 Combination therapy
AU2012206945A AU2012206945B2 (en) 2011-01-11 2012-01-11 Combination therapy

Publications (2)

Publication Number Publication Date
AU2012206945A1 AU2012206945A1 (en) 2013-07-04
AU2012206945B2 true AU2012206945B2 (en) 2015-02-19

Family

ID=46506697

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012206945A Active AU2012206945B2 (en) 2011-01-11 2012-01-11 Combination therapy

Country Status (9)

Country Link
US (6) US9314450B2 (enExample)
EP (3) EP3586844A1 (enExample)
JP (4) JP6087836B2 (enExample)
CN (2) CN103476410B (enExample)
AU (1) AU2012206945B2 (enExample)
CA (1) CA2821985C (enExample)
IL (1) IL227414A (enExample)
WO (1) WO2012094703A1 (enExample)
ZA (1) ZA201305897B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547366A4 (en) 2010-03-18 2013-08-07 Univ Colorado State Res Found SUPPRESSOR CELL HEMMER OBTAINED FROM MYELOID CELLS
EP2726108B1 (en) 2011-06-29 2018-01-10 The Trustees of Columbia University in the City of New York Inhibitor of neuronal connectivity linked to schizophrenia susceptibility and cognitive dysfunction
WO2014021942A1 (en) * 2012-08-01 2014-02-06 University Of Southern California Methods for limiting development of neurodegeneration
WO2014075093A1 (en) * 2012-11-09 2014-05-15 The Trustees Of Columbia University In The City Of New York Inhibitors of central nervous system vasoactive inhibitory peptide receptor 2
JP2014193854A (ja) * 2013-02-28 2014-10-09 Santen Pharmaceut Co Ltd テトラヒドロピラニルアミノシクロペンチルカルボニルテトラヒドロピリドピリジン誘導体を有効成分として含有する後眼部疾患の予防または治療剤
US8975290B2 (en) 2013-03-01 2015-03-10 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
WO2014134621A2 (en) * 2013-03-01 2014-09-04 Colorado State University Research Foundation Methods and compositions for enhancing an immune response, blocking monocyte migration, amplifying vaccine immunity and inhibiting tumor growth and metastasis
CN103193771B (zh) * 2013-03-29 2015-08-05 中国人民解放军军事医学科学院生物工程研究所 链状酰胺类ccr5受体抑制剂的药物新用途
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) * 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
MX2017000580A (es) * 2014-07-17 2017-09-01 Santen Pharmaceutical Co Ltd Agente profilactico o terapeutico para enfermedades del segmento posterior del ojo.
AU2015314830B2 (en) * 2014-09-12 2021-01-07 Tobira Therapeutics, Inc. Cenicriviroc combination therapy for the treatment of fibrosis
EP3349751A4 (en) * 2015-09-16 2019-05-22 Tobira Therapeutics, Inc. CENICRIVIROC COMBINATION THERAPY FOR THE TREATMENT OF FIBROSIS
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
EP3389652B1 (en) 2015-12-14 2022-09-28 X4 Pharmaceuticals, Inc. Methods for treating cancer
ES2935834T3 (es) 2015-12-22 2023-03-10 X4 Pharmaceuticals Inc Métodos para tratar enfermedad de inmunodeficiencia
CN109153722A (zh) 2016-04-08 2019-01-04 X4 制药有限公司 用于治疗癌症的方法
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP4134080B1 (en) 2016-11-23 2024-11-13 ChemoCentryx, Inc. Ccr2 inhibitors for use in treating renal diseases
MX386699B (es) 2017-10-11 2025-03-19 Chemocentryx Inc Tratamiento de glomerulosclerosis segmentaria focal con antagonistas ccr2
CN108218789A (zh) * 2018-03-12 2018-06-29 钦州学院 碳13氘代甲基替米沙坦及其制备方法和用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP7501876B2 (ja) * 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN114466653A (zh) * 2019-09-26 2022-05-10 戴麦里克斯生物科学有限公司 用于治疗疾病的方法和组合物
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
GB202006079D0 (en) * 2020-04-24 2020-06-10 Vicore Pharma Ab New composition
EP4146191A1 (en) * 2020-05-06 2023-03-15 Dimerix Bioscience Pty Ltd Treatment for acute respiratory distress syndrome
WO2021222971A1 (en) * 2020-05-06 2021-11-11 Dimerix Bioscience Ltd Treatment for virus induced acute respiratory distress syndrome
CN117042763A (zh) * 2021-03-23 2023-11-10 戴麦里克斯生物科学有限公司 炎性疾病的治疗
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd
TW202444344A (zh) * 2023-05-12 2024-11-16 澳大利亞商迪美力士生物科技有限公司 用於腎病之治療調配物
CN117054652B (zh) * 2023-08-04 2024-05-17 南京医科大学 一种用于辅助检测心肌肥厚的生物标志物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422228A1 (en) * 2001-08-08 2004-05-26 Takeda Chemical Industries, Ltd. BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
WO2008060621A2 (en) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
WO2009073683A2 (en) * 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
WO2010108232A1 (en) * 2009-03-27 2010-09-30 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
JP2876058B2 (ja) 1986-08-18 1999-03-31 エミスフィア・テクノロジーズ・インコーポレイテッド 薬物送達システム
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
US5492904A (en) * 1991-05-15 1996-02-20 E. I. Du Pont De Nemours And Company Composition of angiotensin-II receptor antagonists and calcium channel blockers
JPH059116A (ja) 1991-07-01 1993-01-19 Sanwa Kagaku Kenkyusho Co Ltd ３−オキシゲルミルプロピオン酸組成物並びに該組成物を主成分とする細胞変性抑制剤
PT831911E (pt) * 1995-06-07 2002-09-30 Searle & Co Terapeutica de combinacao de espironolactona e antagonista da angiotensina ii para o tratamento de insuficiencia cardiaca congestiva
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
WO2000025134A1 (en) 1998-10-23 2000-05-04 Glaxo Group Limited Assays for ligands for nuclear receptors
DE60130538T2 (de) * 2000-02-03 2008-06-12 Millenium Pharmaceuticals, Inc., Cambridge Humanisierte antikörper gegen ccr2 und verfahren zur deren verwendung
US6893827B1 (en) 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
EP1481996A1 (en) 2003-05-30 2004-12-01 KRATON Polymers Research B.V. Process for making a coupled block copolymer composition
WO2005007822A2 (en) 2003-07-09 2005-01-27 Sentigen Biosciences, Inc. Method for assaying protein-protein interaction
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
WO2005050182A1 (en) 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
JP2006008568A (ja) 2004-06-24 2006-01-12 Cyclochem:Kk ＩｇＥ抗体抑制剤および食品
EP1787647B1 (en) * 2004-09-06 2012-06-20 Kowa Company, Ltd. Remedy for glomerular diseases
AR050631A1 (es) 2004-09-09 2006-11-08 Novartis Ag Combinacion de compuestos organicos
GB0612630D0 (en) * 2006-06-26 2006-08-02 Novartis Ag Organic compounds
US8058873B2 (en) 2006-11-10 2011-11-15 Koninklijke Philips Electronics N.V. Prevention quench in a magnetic resonance examination system
US8283127B2 (en) 2006-11-10 2012-10-09 Dimerix Bioscience Pty Ltd. Detection system and uses therefor
WO2008113095A1 (en) 2007-03-20 2008-09-25 Fibrotech Therapeutics Pty Ltd Compositions and therapies comprising tranilast compounds and angiotensin-converting enzyme (ace) inhibitors and/or angiotensin receptor blockers (arb)
US20110092463A1 (en) 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
EP2389178A4 (en) 2008-12-01 2012-06-06 Invasc Therapeutic Inc COMPOSITIONS CONTAINING INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM AND LIPOIC ACID COMPOUNDS, AND THEIR USE FOR THE TREATMENT OF RENIN-ANGIOTENSIN-ALDOSTERONE ASSOCIATED DISORDERS
US8537791B2 (en) 2009-01-20 2013-09-17 Lg Electronics Inc. Method and apparatus for channel access in contention-based communication system and station

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1422228A1 (en) * 2001-08-08 2004-05-26 Takeda Chemical Industries, Ltd. BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
WO2008060621A2 (en) * 2006-11-17 2008-05-22 Abbott Laboratories Aminopyrrolidines as chemokine receptor antagonists
WO2009042193A1 (en) * 2007-09-25 2009-04-02 Abbott Laboratories Octahydropentalene compounds as chemokine receptor antagonists
WO2009073683A2 (en) * 2007-12-04 2009-06-11 Schering Corporation Methods of treating copd
WO2010108232A1 (en) * 2009-03-27 2010-09-30 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers

Also Published As

Publication number Publication date
AU2012206945A1 (en) 2013-07-04
JP2020122015A (ja) 2020-08-13
EP3586844A1 (en) 2020-01-01
US20180000826A1 (en) 2018-01-04
WO2012094703A1 (en) 2012-07-19
US20160243127A1 (en) 2016-08-25
EP2663304A4 (en) 2014-06-25
JP6087836B2 (ja) 2017-03-01
IL227414A (en) 2017-06-29
EP2663304A1 (en) 2013-11-20
CA2821985A1 (en) 2012-07-19
US20240366570A1 (en) 2024-11-07
CN107899012A (zh) 2018-04-13
US20200046685A1 (en) 2020-02-13
IL227414A0 (en) 2013-09-30
JP2018127498A (ja) 2018-08-16
US10525038B2 (en) 2020-01-07
US12083102B2 (en) 2024-09-10
US11382896B2 (en) 2022-07-12
US9314450B2 (en) 2016-04-19
US20130289084A1 (en) 2013-10-31
CN103476410A (zh) 2013-12-25
CA2821985C (en) 2019-07-09
ZA201305897B (en) 2014-04-30
EP4215194A1 (en) 2023-07-26
CN103476410B (zh) 2020-02-21
JP2017078085A (ja) 2017-04-27
US10058555B2 (en) 2018-08-28
JP2014505049A (ja) 2014-02-27
US20220323418A1 (en) 2022-10-13
EP2663304B1 (en) 2019-11-20

Similar Documents

Publication Publication Date Title
US12083102B2 (en) Method for treating inflammatory disorders
US20220226293A1 (en) Treatments of angioedema
US20230381162A1 (en) Treatments of angioedema
JP2014098016A (ja) 高血圧と代謝症候群の治療に用いられる薬物組成物及びその応用
US20240173302A1 (en) Treatment of inflammatory diseases
KR20220070435A (ko) 질환의 치료를 위한 방법 및 조성물
WO2021222972A1 (en) Treatment for acute respiratory distress syndrome
HK1192712A (en) Combination therapy
HK1192712B (en) Combination therapy
ES2770785T3 (es) Terapia de combinación
WO2021222971A1 (en) Treatment for virus induced acute respiratory distress syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)